Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Learn about the flu shot, COVID-19 vaccine, and our masking policy »
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Get the iPhone MyHealth app »
Get the Android MyHealth app »
NRG-RTOG 1106/ACRIN 6697: A phase IIR trial of standard versus adaptive (mid-treatment PET-based) chemoradiotherapy for stage III NSCLC-Results and comparison to NRG-RTOG 0617 (non-personalized RT dose escalation). Kong, F., Hu, C., Ten Haken, R., Xiao, Y., Matuszak, M., Hirsh, V., Pryma, D. A., Siegel, B. A., Gelblum, D. Y., Hayman, J., Robinson, C., Loo, B. W., Videtic, G. M., Faria, S., Ferguson, C., Dunlap, N. E., Kundapur, V., Paulus, R., Bradley, J. D., Machtay, M. LIPPINCOTT WILLIAMS & WILKINS. 2021
View details for DOI 10.1200/JCO.2021.39.15_suppl.8548
View details for Web of Science ID 000708120604262